Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pseudomonas aeruginosa injection versus fosfomycin tromethamine for prevention of recurrent urinary tract infection
ChiCTR2000040867Phase 4Recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Dec 2020
- Modality
- Small Molecules, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pseudomonas aeruginosa injection and fosfomycin in urinary tract infection (UTI) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: Urine secretory IgA and Peripheral blood T-cell subsets. Started Dec 2020; status: recruiting.
02
Drugs
pseudomonas aeruginosa injectionfosfomycin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on ChiCTR2000040867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040867.